Clostridium difficile infection: historic review.

J. Bartlett

DOI: https://doi.org/10.1016/j.anaerobe.2009.09.004

IF: 2.837

2009-12-01

Anaerobe

Abstract:

What problem does this paper attempt to address?

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

Libor Vitek,Cristina Bellarosa,Claudio Tiribelli

DOI: https://doi.org/10.1002/cpt.1341

2019-03-01

Abstract:Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5'-diphospho-glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP-glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation-mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress-mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.

pharmacology & pharmacy
[Computer sharing among laboratories--TCLC system].

T. Ueda,T. Miyaji,M. Komeoka,Y. Yonehara,T. Fukuda

1971-08-01

Abstract:
Can transcutaneous bilirubinometry safely be used to monitor rebound hyperbilirubinaemia after phototherapy in neonates ≥35 weeks’ gestation? A prospective, comparative study

Frances Rose Butterworth,Richard Boulton,Shona Campbell,Gillian Frew,Helen Mactier

DOI: https://doi.org/10.1136/archdischild-2023-326145

2024-04-10

Archives of Disease in Childhood - Fetal and Neonatal Edition

Abstract:Introduction There is insufficient evidence to determine if non-invasive transcutaneous bilirubin (TcB) measurement can replace serum bilirubin (SBR) in assessing rebound hyperbilirubinaemia after phototherapy. Objective To investigate if TcB can safely guide management of neonates after phototherapy. Subjects 100 well neonates ≥35 weeks’ gestation who had received inpatient phototherapy. Method Measurement of both helix (manufacturer’s recommendation) and earlobe TcB coincidentally with routine SBR 12 hours after cessation of phototherapy. All mothers gave written informed consent. Results Gestation ranged from 35 +0 to 41 +5 (median 37 +6 ) weeks; birth weight 2018–4566 (median 3230) g; age 55–222 (median 109) hours at testing. 86% neonates were Caucasian. Outcomes determined by SBR included restarting phototherapy (n=0), repeat SBR next day (n=29), no further routine follow-up (n=71). TcB and SBR measurements were unpredictably inconsistent. Helix TcB tended to underestimate SBR (mean difference 50.1 (95% CI 113.9 to -13.7) μmols/L); for earlobe TcB mean difference was -13.4 (95% CI 46.3 to -73.2) μmols/L (overestimate), but bias was greater over the range of mean differences. No demographic factor predicted consistency between TcB and SBR. TcB was 25% (helix) and 76% (earlobe) sensitive in predicting repeat phototherapy and/or repeat SBR; specificities were 92% and 58%, respectively. Adding a safety margin of 120 μmols/L to helix TcB value could have safely avoided invasive SBR measurement in 50/98 (51%) babies. Conclusions Consistency between TcB and rebound SBR is unpredictable in well neonates > 35 weeks’ gestation but adopting a wide safety margin has potential to reduce blood sampling. Recommencement of phototherapy is uncommon in this population.

pediatrics
A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

T Miyakoshi,Y Mutsuda,Y Horiuchi,T Kameda,M Tozuka,R Ohkawa

DOI: https://doi.org/10.1093/clinchem/hvad097.188

IF: 12.114

2023-09-27

Clinical Chemistry

Abstract:Abstract Background High density lipoprotein (HDL) exerts various atheroprotective functions including cholesterol efflux capacity (CEC). HDL can attenuate lipid burden at atherosclerotic lesion by CEC. Based on the HDL`s role for moderate atherosclerosis, HDL-cholesterol level which indicates the amount of HDL has been evaluated to assess the risk of cardiovascular disease (CVD). Nevertheless, many clinical studies demonstrated that HDL-cholesterol level does not always reflect the risk of CVD, and CEC which represents the quality of HDL is considered as surrogate biomarker for CVD. CEC is prospective biomarker for CVD risk assessment, however, CEC measurement encounters barriers for clinical application because of its requirements of cultured cell and radioactive substance for conventional CEC assay. To overcome these problems, we invented a novel CEC assay called immobilized liposome-bound gel beads (ILG) method. This method is cell-free assay and utilizes a fluorescence substance as cholesterol tracer. Although the ILG method is useful assay for clinical application, previous study revealed that bilirubin caused false positive error on CEC value. Hence, current ILG method might produce incorrect CEC evaluation for patients with hyperbilirubinemia and even healthy subjects within the range of biological variation of bilirubin. In this study, we improved the influence of bilirubin for ILG method by using bilirubin oxidase (BOD). Methods BOD (Asahi Kasei Corp.) was added to 10 mM Tris-HCl (pH 7.4) containing 150 mM of NaCl and 1 mM of Na2EDTA (Buffer A). Bilirubin from ‘Interference check A Plus’ (Sysmex Inc.) was added to serum (free-: 10 mg/dL, conjugated-:9.7 mg/dL), and apoB-depleted serum (BDS) was derived from the bilirubin additive serum using polyethylene glycol. After the prepared bilirubin additive BDS was incubated with BOD-containing Buffer A for 16 h, the absorbance spectrum was analyzed. In addition, the time course of bilirubin decrement was monitored during 16 h-incubation. We further measured the fluorescence intensity of bilirubin additive BDS incubated with BOD-containing Buffer A. Using the newly developed BOD-containing Buffer A for ILG method, CEC of bilirubin additive serum was evaluated. Finally, we measured CEC of 4 healthy individuals by conventional and the improved ILG method. The CEC value was standardized by fluorescence intensity of reference sample which was measured in every assay. Results BOD contained in Buffer A could convert bilirubin to biliverdin from results of absorbance spectrum. According to the time course of bilirubin decrement, both free- and conjugated-bilirubin were oxidized to biliverdin in approximately 6 h. By converting bilirubin to biliverdin, fluorescence light was weakened greatly. We confirmed that there was no significant difference of CEC values between non bilirubin-additive serum and bilirubin additive serum. Compared healthy individual CEC values measured by conventional and improved ILG method, all subjects showed significant decrease of CEC values from the improved method, and false positive error caused by bilirubin was ameliorated. Conclusion In this study, we achieved to improve the positive error caused by bilirubin on CEC assay using ILG method. This improvement would contribute to more accurate CEC assessment by ILG method and advance the clinical application of this method.

medical laboratory technology
Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease

Annalisa Bianco,Claudio Tiribelli,Cristina Bellarosa

DOI: https://doi.org/10.3390/biomedicines10030696

IF: 4.757

2022-03-17

Biomedicines

Abstract:Bilirubin has been regarded as a powerful endogenous antioxidant and anti-inflammatory molecule, able to act on cellular pathways as a hormone. Diabetic kidney disease (DKD) is a common chronic complication of diabetes, and it is the leading cause of end-stage renal disease. Here, we will review the clinical and molecular features of mild hyperbilirubinemia in DKD. The pathogenesis of DKD involves oxidative stress, inflammation, fibrosis, and apoptosis. Serum bilirubin levels are positively correlated with the levels of the antioxidative enzymes as superoxide dismutase, catalase, and glutathione peroxidase, while it is inversely correlated with C-reactive protein, TNF-α, interleukin (IL)-2, IL-6, and IL-10 release in diabetic kidney disease. Bilirubin downregulates NADPH oxidase, reduces the induction of pro-fibrotic factor HIF-1α expression, cleaved caspase-3, and cleaved PARP induction showing lower DNA fragmentation. Recent experimental and clinical studies have demonstrated its effects in the development and progression of renal diseases, pointing out that only very mild elevations of bilirubin concentrations result in real clinical benefits. Future controlled studies are needed to explore the precise role of bilirubin in the pathogenesis of DKD and to understand if the use of serum bilirubin levels as a marker of progression or therapeutic target in DKD is feasible and realistic.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
A method for red blood cell biotinylation in a closed system

Djuna Z de Back,Richard Vlaar,Boukje Beuger,Brunette Daal,Johan Lagerberg,Alexander P J Vlaar,Dirk de Korte,Marian van Kraaij,Robin van Bruggen

DOI: https://doi.org/10.1111/trf.14535

Transfusion

Abstract:Background: Several circumstances require the accurate measurement of red blood cell (RBC) survival and clearance, such as determination of posttransfusion recovery of stored RBCs to investigate the effect of new additive solutions. To this end, biotin as a marker of RBCs to track donor RBCs in the blood of the recipient has been used in many studies. However, so far only experimental, nonvalidated, biotin-labeled red cell concentrates (RCCs) are transfused. The goal of this study was to produce a standardized biotin-labeled RCC product in a fast, simple, and sterile manner that can be used for clinical research and for the evaluation of new blood products according to Good Practice Guidelines (GPG) for blood establishments. Study design and methods: RCC fractions were labeled with two different concentrations of biotinylation reagent in a closed system, to prevent bacterial contamination of the end product. Using flow cytometry, the reproducibility and robustness of the biotin labeling was assessed, as well as the stability of the biotin label on the (un-)irradiated RCC fraction. Additionally, parameters such as phosphatidylserine (PS) exposure, sodium (Na), potassium (K), free hemoglobin, adenosine triphosphate (ATP), pH, and morphology were determined prior to and after biotin labeling to rule out detrimental effects of the labeling procedure on the RCC. Results: Our data show that RCCs can be labeled under sterile conditions in a closed system with two different biotinylation reagent concentrations, without affecting the biological activity. Conclusion: An easy, rapid (<2 hr), and robust method was developed to manufacture biotin-labeled RCCs for clinical research compliant to GPG.
A novel optical assay system for bilirubin concentration measurement in whole blood

Jean Pierre Ndabakuranye,Anushi E. Rajapaksa,Genia Burchall,Shiqiang Li,Steven Prawer,Arman Ahnood

DOI: https://doi.org/10.1109/TBME.2021.3111150

2024-06-21

Abstract:As a biomarker for liver disease, bilirubin has been utilized in prognostic scoring systems for cirrhosis. While laboratory-based methods are used to determine bilirubin levels in clinical settings, they do not readily lend themselves to applications outside of hospitals. Consequently, bilirubin monitoring for cirrhotic patients is often performed only intermittently; thus, episodes requiring clinical interventions could be missed. This work investigates the feasibility of measuring bilirubin concentration in whole porcine blood samples using dual-wavelength transmission measurement. A compact and low-cost dual-wavelength transmission measurement setup is developed and optimized to measure whole blood bilirubin concentrations. Using small volumes of whole porcine blood (72 {\mu}L), we measured the bilirubin concentration within a range corresponding to healthy individuals and cirrhotic patients (1.2-30 mg/dL). We demonstrate that bilirubin levels can be estimated with a positive correlation (R-square > 0.95) and an accuracy of +/- 1.7 mg/dL, with higher reliability in cirrhotic bilirubin concentrations (> 4 mg/dL), critical for high-risk patients. The optical and electronic components utilized are economical and can be readily integrated into a miniature, low-cost, and user-friendly system. This could provide a pathway for point-of-care monitoring of blood bilirubin outside of medical facilities.

Medical Physics,Signal Processing,Biological Physics
Simultaneous Determination of Bilirubin and Its Glucuronides in Liver Microsomes and Recombinant UGT1A1 Enzyme Incubation Systems by HPLC Method and Its Application to Bilirubin Glucuronidation Studies

Guo Ma,Jiayuan Lin,Weimin Cai,Bo Tan,Xiaoqiang Xiang,Ying Zhang,Peng Zhang

DOI: https://doi.org/10.1016/j.jpba.2014.01.025

IF: 3.571

2014-01-01

Journal of Pharmaceutical and Biomedical Analysis

Abstract:Bilirubin, an important endogenous substances and liver function index in humans, is primarily eliminated via UGT1A1-catalyzed glucuronidation. Instability of bilirubin and its glucuronides brings substantial technical challenges to conduct in vitro bilirubin glucuronidation assay. In the present study, we developed a simple and robust HPLC method for simultaneous determination of unconjugated bilirubin (UCB) and its multiple glucuronides, i.e. bilirubin monoglucuronides (BMGs, including BMG1 and BMG2 isomers) and diglucuronicie (BDG) in rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human UGT1A1 enzyme (UGT1A1) incubation systems, and applied it to study in vitro bilirubin glucuronidation. UCB, BMG1, BMG2, BDG and their isomers in the incubation mixtures were successfully separated using a C18 column with UV detection at 450 nm and mobile phase consisted of 0.1% formic acid in water and acetonitrile by a linear gradient elution program. Assay linearities of bilirubin were confirmed in the range 0.01-2 mu M. Precision of UCB, BMG1, BMG2 and BDG (n = 5) at low, medium and high concentration was within the range of RSD 0.4-3.7%, accuracy expressed in the mean assay recoveries of them (n = 5) ranged from 92.8 +/- 1.5% to 104.3 +/- 2.2% for intra- and inter-day assays and the mean extraction recoveries of them (n = 5) were above 91.5 +/- 1.0%. Stability of bilirubin and its glucuronides was satisfactory at 37 degrees C in the incubation solutions during the reaction (30 min), 25 degrees C for 24 h and -70 degrees C for 7 d in the processed incubation samples with methanol. Furthermore, we established stable, reliable in vitro incubation systems and optimized the incubation conditions to characterize the kinetics of bilirubin glucuronidation by RLM, HLM and UGT1A1, respectively. The kinetic parameters of formation of total bilirubin glucuronides (TBG, the sum of BMG1, BMG2 and BDG) were as follows: K-m of 0.45 +/- 0.016, 0.40 +/- 0.022, 0.44 +/- 0.018 mu M, V-max of 2.65 +/- 0.057, 1.86 +/- 0.029, 2.95 +/- 0.036 nmol/mg/min, CLint of 5.92 +/- 0.22, 4.70 +/- 0.079, 6.72 +/- 0.27 mL/mg/min by RLM, HLM and UGT1A1, respectively. Bilirubin glucuronidation obeyed the Hill equation by RLM and the Michaelis-Menten equation by HLM and UGT1A1 in the range of substrate concentration selected, respectively. In addition, the relative proportions between BDG and BMGs were in connection with enzyme sources (e.g. RLM, HLM and UGT1A1) and bilirubin concentration. (C) 2014 Elsevier B.V. All rights reserved.
Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia

Ryoichi Fujiwara,Mathias Haag,Elke Schaeffeler,Anne T. Nies,Ulrich M. Zanger,Matthias Schwab

DOI: https://doi.org/10.1002/hep.29599

IF: 17.298

2018-03-02

Hepatology

Abstract:Neurotoxic bilirubin is the end product of heme catabolism in mammals. Bilirubin is solely conjugated by uridine diphospho-glucuronosyltransferase 1A1, which is a membrane-bound enzyme that catalyzes the transfer of glucuronic acid. Due to low function of hepatic and intestinal uridine diphospho-glucuronosyltransferase 1A1 during the neonatal period, human neonates develop mild to severe physiological hyperbilirubinemia. Accumulation of bilirubin in the brain leads to the onset of irreversible brain damage, termed kernicterus. Breastfeeding is one of the most significant factors that increase the risk of developing kernicterus in infants. Why does this most natural way of feeding increase the risk of brain damage or even death? This question leads to the hypothesis that breast milk-induced hyperbilirubinemia might bring certain benefits that outweigh those risks. While bilirubin is neurotoxic and cytotoxic, this compound is also a potent antioxidant. There are studies showing improved clinical conditions in patients with hyperbilirubinemia. Accumulating evidence also shows that genetic polymorphisms linked to hyperbilirubinemia are beneficial against various diseases. In this review article, we first introduce the production, metabolism, and transport of bilirubin. We then discuss the potential benefits of neonatal and adult hyperbilirubinemia. Finally, epigenetic factors as well as metabolomic information associated with hyperbilirubinemia are described. This review article advances the understanding of the physiological importance of the paradoxical compound bilirubin. (Hepatology 2018;67:1609-1619).

gastroenterology & hepatology
Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study

Erum A. Hartung,Matthew B. Matheson,M. Lande,K. Dell,L. Guay-Woodford,A. Gerson,B. Warady,S. Hooper,S. Furth

DOI: https://doi.org/10.1007/s00467-014-2816-5

2014-05-15

Abstract:
Issues for standardization of neonatal bilirubinemia: a case of delayed phototherapy initiation

Michel Vaubourdolle,Agnès Mailloux

DOI: https://doi.org/10.1515/cclm-2023-1444

2024-03-30

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:Research ethics: Not applicable. Informed consent: Not applicable. Author contributions: All authors contributed with analysis and interpretation of data, provided intellectual content of critical importance to the work described, revising the article and have accepted responsibility for the entire content of this manuscript and approved its submission. Competing interests: The authors state no conflict of interest. Research funding: None declared. Data availability: The raw data can be obtained on request from the corresponding author. 1. Mollison, PL, Walker, W. Controlled trials of the treatment of hemolytic disease of the newborn. Lancet 1952;1:429–33. https://doi.org/10.1016/s0140-6736(52)91949-1. Search in Google Scholar PubMed 2. Cortey, A. Kernicterus: the comeback. Arch Pediatr 2012;19:897–9. https://doi.org/10.1016/j.arcped.2012.06.018. Search in Google Scholar PubMed 3. Bhutani, VK, Johnson, L. A proposal to prevent severe neonatal hyperbilirubinemia and kernicterus. J Perinatol 2009;29(Supplement 1):S61–7. https://doi.org/10.1038/jp.2008.213. Search in Google Scholar PubMed 4. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia . Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears in Pediatrics. 2004; 114:1138]. Pediatrics 2004;114:297–316. https://doi.org/10.1542/peds.114.1.297. Search in Google Scholar PubMed 5. Mailloux, A. What to expect from a bilirubin analysis for management of Jaundiced Newborns? Clin Biochem 2014;47:751–2. https://doi.org/10.1016/j.clinbiochem.2014.05.043. Search in Google Scholar PubMed 6. Cobbaert, C, Weykamp, C, Hulzebos, CV. Bilirubin standardization in The Netherlands: alignment within and between manufacturers. Clin Chem 2010;56:872–3. https://doi.org/10.1373/clinchem.2009.142059. Search in Google Scholar PubMed 7. Mailloux, A, Cortey, A, Delatour, V, Poupon, C, Rota, M, Schmitt, F, et al.. Recommandations analytiques et cliniques pour l'utilisation de la bilirubinémie en néonatalogie. Ann Biol Clin 2020;78:383–97. https://doi.org/10.1684/abc.2020.1571. Search in Google Scholar PubMed 8. Vaubourdolle, M, Mailloux, A. Intérêt de la bilirubinémie en néonatalogie : recommandations pour une utilisation coordonnée par le LBM de la biologie délocalisée et des tests rapides d'orientation diagnostique. Ann Biol Clin 2022;80:509–19. https://doi.org/10.1684/abc.2022.1774. Search in Google Scholar PubMed 9. Thomas, M, Greaves, RF, Tingay, DG, Loh, TP, Ignjatovic, V, Newall, F, et al.. Current and emerging technologies for the timely screening and diagnosis of neonatal jaundice. Crit Rev Clin Lab 2022;59:332–52. https://doi.org/10.1080/10408363.2022.2038074. Search in Google Scholar PubMed © 2024 Walter de Gruyter GmbH, Berlin/Boston

medical laboratory technology
Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.

Holger Fuchs,Frederik Igney

DOI: https://doi.org/10.1089/jop.2016.0083

2017-03-01

Journal of Ocular Pharmacology and Therapeutics

Abstract:PURPOSE The ocular half-life of intravitreally (IVT) injected drugs is of major relevance for the suitability of a drug intended for chronic intraocular treatment, as the half-life determines the dosing frequency. Thus, half-life extension principles are very attractive as they can reduce the IVT dosing frequency. In this study, we investigated the ocular pharmacokinetics (PK) of the IVT injected Nanobody® BI-X and whether the noncovalent binding of BI-X to vitreous albumin could increase its ocular half-life. METHODS Wistar rats were dosed IVT with 3 μg BI-X alone or coadministered with human serum albumin (HSA), and the ocular exposure was measured in a pilot experiment using whole eye homogenates. New Zealand White rabbits received IVT injections of 500 μg BI-X alone or coadministration with HSA. Concentrations of BI-X were determined in aqueous humor, vitreous body and plasma and pharmacokinetic parameters were calculated. RESULTS Ocular concentrations of BI-X in rats were about 10- or 3-fold higher at 24 and 72 h, respectively, when dosed with HSA. In rabbits, coadministration with albumin led to an about 3-fold increased vitreous half-life and an about 5-fold higher exposure in vitreous humor. CONCLUSION As small amounts of albumin are present in the vitreous body of healthy human eyes and the albumin concentration is even increased under disease conditions like diabetic retinopathy, high affinity binding to albumin may be a promising strategy to extend the half-life of IVT injected drugs, allowing for longer dosing intervals.

Chemistry,Medicine
Time to refresh and integrate the JCTLM database entries for total bilirubin: the way forward

Mauro Panteghini,W. Greg Miller,Robert Wielgosz

DOI: https://doi.org/10.1515/cclm-2024-1110

2024-10-10

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:The authors acknowledge the support of Stanley F. Lo in improving the knowledge about the original Doumas method. Research ethics: Not applicable. Informed consent: Not applicable. Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission. Use of Large Language Models, AI and Machine Learning Tools: None declared. Conflict of interest: The authors state no conflict of interest. Research funding: None declared. Data availability: Not applicable. 1. Doumas, BT, Kwok-Cheung, PP, Perry, BW, Jendrzejczak, B, McComb, RB, Schaffer, R, et al.. Candidate reference method for determination of total bilirubin in serum: development and validation. Clin Chem 1985;31:1779–89. https://doi.org/10.1093/clinchem/31.11.1779. Search in Google Scholar 2. ISO 17511:2020 . In vitro diagnostic medical devices — requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples . Geneva, Switzerland: International Organization for Standardization (ISO); 2020. Search in Google Scholar 3. Panteghini, M, Braga, F, Camara, JE, Delatour, V, Van Uytfanghe, K, Vesper, HW, JCTLM Task Force on Reference Measurement System Implementation , et al.. Optimizing available tools for achieving result standardization: value added by joint committee on traceability in laboratory medicine (JCTLM). Clin Chem 2021;67:1590–605. https://doi.org/10.1093/clinchem/hvab178. Search in Google Scholar PubMed 4. Hulzebos, CV, Camara, JE, van Berkel, M, Delatour, V, Lo, SF, Mailloux, A, IFCC Working Group Neonatal Bilirubin , et al.. Bilirubin measurements in neonates: uniform neonatal treatment can only be achieved by improved standardization. Clin Chem Lab Med 2024;62:1892–903. https://doi.org/10.1515/cclm-2024-0620. Search in Google Scholar PubMed 5. Klauke, R, Kytzia, HJ, Weber, F, Grote-Koska, D, Brand, K, Schumann, G. Reference measurement procedure for total bilirubin in serum re-evaluated and measurement uncertainty determined. Clin Chim Acta 2018;481:115–20. https://doi.org/10.1016/j.cca.2018.02.037. Search in Google Scholar PubMed 6. Panteghini, M, Camara, JE, Delatour, V, Van Uytfanghe, K, Vesper, HW, Zhang, T. Feasibility of metrological traceability implementation using the Joint Committee on Traceability in Laboratory Medicine (JCTLM) database entries including the fulfillment of 'fit-for-purpose' maximum allowable measurement uncertainty. Clin Chem 2024:hvae131. https://doi.org/10.1093/clinchem/hvae131. Search in Google Scholar PubMed 7. Mailloux, A, Cortey, A, Delatour, V, Poupon, C, Rota, M, Schmitt, F, et al.. Analytical and clinical guidelines on neonatal bilirubinemia. Ann Biol Clin 2020;78:383–97. https://doi.org/10.1684/abc.2020.1571. Search in Google Scholar PubMed 8. Farrell, CJL, Jones, GRD, Sikaris, KA, Badrick, T, Graham, P, Bush, J. Sharing reference intervals and monitoring patients across laboratories – findings from a likely commutable external quality assurance program. Clin Chem Lab Med 2024;62:2037–47. https://doi.org/10.1515/cclm-2024-0041. Search in Google Scholar PubMed 9. Vaubourdolle, M, Mailloux, A. Issues for standardization of neonatal bilirubinemia: a case of delayed phototherapy initiation. Clin Chem Lab Med 2024;62:e221–4. https://doi.org/10.1515/cclm-2023-1444. Search in Google Scholar PubMed 10. Oostendorp, M, Ten Hove, CH, van Berkel, M, Roovers, L. A significant increase in the incidence of neonatal hyperbilirubinemia and -Abstract Truncated-

medical laboratory technology
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial

Torp,N.,Israelsen,M.,Coenraad,M.,Papp,M.,Shawcross,D.,Korenjak,M.,Angeli,P.,Laleman,W.,Juanola,A.,Gines,P.,Trebicka,J.,Krag,A.,MICROB-PREDICT Consortium,Arroyo,Sanchez-Garrido,Aguilar-Parera,Sierra-Casas,Trebicka,Bosch-Comas,Papp,Tornai,Balogh,Krag,Torp,Thiele,Thorhauge,Israelsen,Poulsen,Juel,Hansen,Alvarez-Silva,Arumugam,Bork,Kandels,Kuhn,Rossum,Nishijima,Keller,Hazenbrink,Junot,Fenaille,Dechaumet,Burz,Castelli,Chu-Van,Thevenot,Pruvost,Rosenberger,Treit,Geyer,Mann,Lelouvier,Servant,Blerk,Ouzerdine,Roulet,Insonere,Serres,Laiola,Almeida,Thirion,Champion,Blottiere,Ezzine,Chamignon,Lapaque,Thiam,Galleron,Quinquis,Espen,Laleman,Matthijnssens,Coenraad,Kuijper,Ducarmon,Broekhoven,Fischer,Zwittink,Lecuona,Letunic,Rosati,Fuentes-Chust,Merkoci,Urban,Marrugo-Ramirez,Melberg,Asphaug,Korenjak,Schwalber,Shawcross,Patel,McPhail,Edwards,Kronsten,Moyes,Shoaie,Harzandi,Juanola,Pose,Gratacos-Gines,Perez-Guasch,Gines,Pellon,Claria,Lopez-Vicario,Contreras,Klein,Schierwagen,Gu,Uschner,Brol,Praktiknjo,Fobker,Feuerborn

DOI: https://doi.org/10.1136/bmjopen-2023-079309

IF: 3.006

2024-02-15

BMJ Open

Abstract:Introduction Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine approach with biomarkers to predict human albumin treatment response, so-called predictive biomarkers, could make this a viable treatment option in patients with cirrhosis and ascites. Methods and analysis ALB-TRIAL is a multinational, double-blind, placebo-controlled randomised controlled trial. We aim to validate a predictive biomarker, consisting of a panel of circulating metabolites, to predict the treatment response to human albumin in patients with cirrhosis and ascites. All enrolled patients are stratified into a high-expected or low-expected effect stratum of human albumin based on the biomarker outcome. After stratification, patients in each group are randomised into either active treatment (20% human albumin) or corresponding placebo (0.9% NaCl) every 10th day for 6 months. The primary outcome is the cumulative number of liver-related events (composite of decompensation episodes, transjugular intrahepatic shunt insertion, liver transplantation and death). Key secondary outcomes include time-to-event analysis of primary outcome components, an analysis of the total healthcare burden and a health economic analysis. Ethics and dissemination The trial obtained ethical and regulatory approval in Denmark, Germany, the Netherlands, Belgium, Hungary and Spain through the Clinical Trials Information System (CTIS) from 13 February 2023, while UK approvals from the Health Regulatory Authority, Medicines and Healthcare products Regulatory Agency and Research Ethics Committee are pending. Findings will be published in peer-reviewed journals, presented at conferences, communicated to relevant stakeholders and in the public registry of CTIS, following trial completion. Trial registration number NCT05056220 EU CT: 2022-501006-34-01

medicine, general & internal
The positive influence of electrochemical cyclic potentiodynamic passivation (CPP) of a SS316LS surface on its response to fibronectin and pre-osteoblasts.

A. Shahryari,F. Azari,H. Vali,S. Omanovic

DOI: https://doi.org/10.1039/b902881a

2009-08-07

Abstract:The influence of an electrochemical surface passivation technique (cyclic potentiodynamic polarization, CPP) on the physico-chemical surface properties of SS316LS and its subsequent response to fibronectin (Fn) and pre-osteoblasts were investigated. Contact angle and zeta-potential measurements showed that the CPP-modified surface is more hydrophilic and more positively charged than the unmodified surface. Polarization modulation infrared reflection absorption spectroscopy (PM-IRRAS) was used to investigate the interaction of Fn with both surfaces. The saturated surface concentration of adsorbed Fn was higher on the CPP-modified surface. As well, significant changes were identified in the secondary structure of Fn adsorbed on both surfaces, in comparison to its native state. This data also indicated a higher degree of Fn unfolding on the CPP-modified surface. Cell studies indicated that the attachment, proliferation and morphology of pre-osteoblasts were significantly improved on the CPP-modified surface, which was attributed to the more open conformation of Fn on the CPP-modified surface. Thus, the CPP surface passivation method was demonstrated to yield a SS316LS surface of enhanced biocompatibility.
Postgraduate Research Conference

E. Williams,K. Clarke,A. Lorange,Katherine Moline,Wendy Parker,D. Tillman,Mari Velonaki,Stacy Mehrfar,Lynne Roberts-Goodwin,A. Gibson,M. Sims,Jorge Forseck,J. Koh,Emma Crott,T. Ross

Abstract:
Accuracy and Reliability of Whole Blood Bilirubin Measurements Using a Roche Blood Gas Analyzer for Neonatal Hyperbilirubinemia Screening and Risk Stratification

Qing Wang,Tianyi Zhang,Yuanxi Lin,Li Jiang,Wenlong Zhou,Xiaolong Zong

DOI: https://doi.org/10.3389/fped.2022.910566

IF: 3.569

2022-07-04

Frontiers in Pediatrics

Abstract:Background: Accurate bilirubin measurements are essential for appropriate management of neonatal hyperbilirubinemia. This study aimed to evaluate the accuracy and reliability of whole blood bilirubin measurements obtained using a Roche blood gas analyzer (Roche TBiL), with total serum bilirubin (TSB) measurements determined by the Ortho VITROS 4600 chemistry system (Ortho TSB) serving as a reference. Materials and Methods: Medical records of hospitalized neonates that underwent simultaneous Roche TBiL and Ortho TSB measurements were reviewed for eligibility selection and data collection. The correlations and differences between two sets of results were determined using Passing–Bablok regression analysis and a Bland–Altman plot, respectively. For eligible newborns, the risk of developing severe hyperbilirubinemia was assessed using the Bhutani nomogram. Weighted kappa analysis was used to evaluate the agreement between risk prediction by the two methods. Results: We obtained 618 paired Roche TBiL and Ortho TSB results from 309 neonates. Roche TBiL and Ortho TSB measurements showed a good correlation ( r = 0.923; 95% CI: 0.905–0.938). Passing–Bablok regression analysis yielded the following equation: Roche TBiL = 0.794 × Ortho TSB + 1.255 mg/dL, with a slope of 0.794 (95% CI: 0.763–0.825) and intercept of 1.255 (95% CI: 1.042–1.417). The average difference between the two methods was 0.1 ± 1.448 mg/dL. A total of 207 neonates were eligible for evaluation of the agreement between the risk-grading methods. Although kappa analysis showed good agreement between the methods, with a weighted kappa of 0.681 (95% CI: 0.610–0.751) across all populations, the values for approximately half of the neonates at intermediate and high risk of hyperbilirubinemia (33/72) were underestimated by Roche TBiL. Conclusion: Our results indicate that Roche TBiL and Ortho TSB measurements in the neonatal population are not consistent. As a point-of-care and trace blood assay, Roche blood gas bilirubin measurements can facilitate primary screening of neonatal hyperbilirubinemia, but it seems to lack accuracy regarding risk stratification, particularly for high-risk newborn individuals.

pediatrics
Bilirubin lowering effect and safety of a prototype low cost blue light emitting diode (LED) phototherapy device in the treatment of indirect hyperbilirubinemia among healthy term infants in a tertiary government hospital: a pilot study

Vanessa Marie V. Calabia,Ma. Lucila M. Perez,Gregory L. Tangonan Paul M. Cabacungan,Ivan B. Culaba,Jeremy E. De Guzman

DOI: https://doi.org/10.48550/arXiv.2008.08875

2020-08-20

Abstract:Objective: This pilot study was done to evaluate the capability of a prototype low cost blue light emitting diode (LED) phototherapy device in lowering bilirubin levels among healthy term infants diagnosed with indirect hyperbilirubinemia. Methods: Experimental study on term infants diagnosed with indirect hyperbilirubinemia in Ospital ng Makati from May 2016 to November 2016 who underwent phototherapy using the low cost blue LED phototherapy prototype. Results: After 24 hours of phototherapy under the prototype LED phototherapy unit, 16% of the total patients completed treatment as they were already classified in the low risk zone, and another 36% of patients completed treatment after 48 hours. The total bilirubin significantly decreased from baseline bilirubin levels after 24 hours by 16.5% (p = 0.0001). The mean percentage of change of bilirubin reduced after 48 hours of 29.9% was also significant. The proportion of subjects in the high risk zone during baseline to 24th hour went down significantly from 80% to 28% (p = 0.0003), while comparing baseline to 48th hour, the percentage of high risk zone went down from 80% to 9.5% (p = 0.0001). No subjects were reported to have rebound hyperbilirubinemia after discontinuation of phototherapy treatment under the LED prototype. No patient experienced any complication while on phototherapy treatment. Conclusion: The prototype low cost blue light emitting diode (LED) phototherapy was able to lower total serum bilirubin among healthy term infants with indirect hyperbilirubinemia and was safe to use.

Tissues and Organs
Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters

Tomoko Watanabe,Manami Miyake,Toshinobu Shimizu,Miho Kamezawa,Naoya Masutomi,Takesada Shimura,Rikiya Ohashi

DOI: https://doi.org/10.1124/dmd.114.061051

Abstract:It is useful to identify endogenous substrates for the evaluation of drug-drug interactions via transporters. In this study, we investigated the utility of bilirubins, substrates of OATPs and MRP2, and bile acids and substrates of NTCP and BSEP, as biomarkers for the inhibition of transporters. In rats administered 20 and 80 mg/kg rifampicin, the plasma levels of bilirubin glucuronides were elevated, gradually decreased, and almost returned to the baseline level at 24 hours after administration without an elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). This result indicates the transient inhibition of rOatps and/or rMrp2. Although the correlation between free plasma concentrations and IC50 values of rOatps depended on the substrates used in the in vitro studies, the inhibition of rOatps by rifampicin was confirmed in the in vivo study using valsartan as a substrate of rOatps. In rats administered 10 and 30 mg/kg cyclosporin A, the plasma levels of bile acids were elevated and persisted for up to 24 hours after administration without an elevation of ALT and AST. This result indicates the continuous inhibition of rNtcp and/or rBsep, although there were differences between the free plasma or liver concentrations and IC50 values of rNtcp or rBsep, respectively. This study suggests that the monitoring of bilirubins and bile acids in plasma is useful in evaluating the inhibitory potential of their corresponding transporters.
Little known and less understood: the benefits of a lower hematocrit (~40%) in reconstituted blood for double volume exchange transfusion

Jon F. Watchko

DOI: https://doi.org/10.1038/s41372-023-01674-9

2023-04-18

Journal of Perinatology

Abstract:A double volume exchange transfusion (DVET) is an important, if infrequently performed, intervention to acutely lessen the total serum bilirubin (TSB) and reduce the extravascular CNS bilirubin exposure when neonatal hyperbilirubinemia poses a neurotoxicity risk. The current analysis based on the seminal works of Valaes, and Sproul and Smith, predicts that a DVET blood product of lower hematocrit (~40%) via its greater plasma volume and corresponding higher albumin content optimizes the benefits of an DVET in several ways. First, by augmenting bilirubin clearance from the extravascular space and thereby further reducing the CNS bilirubin exposure, second, by favorably positioning the intravascular albumin-bilirubin binding capacity at DVET completion to accommodate additional bilirubin equilibration and rebound hyperbilirubinemia post-exchange, and third by correcting anemia if present.

pediatrics,obstetrics & gynecology

Clostridium difficile infection: historic review.

Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?

[Computer sharing among laboratories--TCLC system].

Can transcutaneous bilirubinometry safely be used to monitor rebound hyperbilirubinaemia after phototherapy in neonates ≥35 weeks’ gestation? A prospective, comparative study

A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease

A method for red blood cell biotinylation in a closed system

A novel optical assay system for bilirubin concentration measurement in whole blood

Simultaneous Determination of Bilirubin and Its Glucuronides in Liver Microsomes and Recombinant UGT1A1 Enzyme Incubation Systems by HPLC Method and Its Application to Bilirubin Glucuronidation Studies

Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia

Neurocognition in children with autosomal recessive polycystic kidney disease in the CKiD cohort study

Issues for standardization of neonatal bilirubinemia: a case of delayed phototherapy initiation

Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit Studies.

Time to refresh and integrate the JCTLM database entries for total bilirubin: the way forward

Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial

The positive influence of electrochemical cyclic potentiodynamic passivation (CPP) of a SS316LS surface on its response to fibronectin and pre-osteoblasts.

Postgraduate Research Conference

Accuracy and Reliability of Whole Blood Bilirubin Measurements Using a Roche Blood Gas Analyzer for Neonatal Hyperbilirubinemia Screening and Risk Stratification

Bilirubin lowering effect and safety of a prototype low cost blue light emitting diode (LED) phototherapy device in the treatment of indirect hyperbilirubinemia among healthy term infants in a tertiary government hospital: a pilot study

Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters

Little known and less understood: the benefits of a lower hematocrit (~40%) in reconstituted blood for double volume exchange transfusion